Welcome to LookChem.com Sign In|Join Free

CAS

  • or

449808-50-8

Post Buying Request

449808-50-8 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

449808-50-8 Usage

Description

6-(2,4-difluorophenoxy)-8-methyl-2-(methylsulfonyl)pyrido[2,3-d]pyrimidin-7(8H)-one is an organic compound that serves as a crucial intermediate in the synthesis of pharmaceuticals, particularly in the development of targeted therapies for various diseases.

Uses

Used in Pharmaceutical Synthesis:
6-(2,4-difluorophenoxy)-8-methyl-2-(methylsulfonyl)pyrido[2,3-d]pyrimidin-7(8H)-one is used as an intermediate in the synthesis of Pamapimod (P167500) for its role as a selective inhibitor of the α-isoform of p38 MAP kinase. This makes it a valuable compound in the development of treatments for conditions where the inhibition of this kinase can provide therapeutic benefits.
Used in Research and Development:
In the field of medicinal chemistry and drug discovery, 6-(2,4-difluorophenoxy)-8-methyl-2-(methylsulfonyl)pyrido[2,3-d]pyrimidin-7(8H)-one is used as a research compound to explore its potential in creating new drugs with improved efficacy and selectivity. Its structural properties allow scientists to investigate its interactions with various biological targets, potentially leading to the discovery of novel therapeutic agents.
Used in the Treatment of Inflammatory Diseases:
Given that Pamapimod, the compound synthesized using 6-(2,4-difluorophenoxy)-8-methyl-2-(methylsulfonyl)pyrido[2,3-d]pyrimidin-7(8H)-one as an intermediate, is a p38 MAP kinase inhibitor, it is likely to be used in the treatment of inflammatory diseases. p38 MAP kinase is involved in the regulation of inflammatory responses, and its inhibition can help manage conditions such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease.
Used in Oncology:
As p38 MAP kinase plays a role in cellular processes like apoptosis, cell proliferation, and differentiation, compounds like Pamapimod that inhibit this kinase may also have applications in oncology. 6-(2,4-difluorophenoxy)-8-methyl-2-(methylsulfonyl)pyrido[2,3-d]pyrimidin-7(8H)-one, by virtue of its role in synthesizing Pamapimod, could contribute to the development of cancer treatments, particularly for tumors where p38 MAP kinase activity is a factor in tumor growth or resistance to chemotherapy.

Check Digit Verification of cas no

The CAS Registry Mumber 449808-50-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,4,9,8,0 and 8 respectively; the second part has 2 digits, 5 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 449808-50:
(8*4)+(7*4)+(6*9)+(5*8)+(4*0)+(3*8)+(2*5)+(1*0)=188
188 % 10 = 8
So 449808-50-8 is a valid CAS Registry Number.

449808-50-8Downstream Products

449808-50-8Relevant articles and documents

Development of radioiodinated pyrimidinopyridone derivatives as targeted imaging probes of activated p38α for single photon emission computed tomography

Hashimoto, Tomoyuki,Kondo, Naoya,Hirata, Masahiko,Temma, Takashi

, p. 1293 - 1304 (2021/08/23)

Objective: p38α, a member of the mitogen-activated protein kinase superfamily, is ubiquitously expressed in a variety of mammalian cells. Activated p38α induces inflammatory responses to external stimuli, suggesting that non-invasive detection of activate

INHIBITORS OF EGFR AND/OR HER2 AND METHODS OF USE

-

Page/Page column 130; 132; 146-147, (2019/03/17)

The application relates to a compound having Formula X: which modulates the activity of HER2 and/or a mutant thereof, and/or EGFR and/or a mutant thereof, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disea

Discovery of 6-(2,4-difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl) propylamino]-8-methyl-8 H -pyrido[2,3- d ]pyrimidin-7-one (pamapimod) and 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2 H -pyran-4-ylamino)pyrido[2,3- d ]pyrimidin-7(8 H)-one (R1487) as orally bioavailable and highly selective inhibitors of p38α mitogen-activated protein kinase

Goldstein, David M.,Soth, Michael,Gabriel, Tobias,Dewdney, Nolan,Kuglstatter, Andreas,Arzeno, Humberto,Chen, Jeffrey,Bingenheimer, William,Dalrymple, Stacie A.,Dunn, James,Farrell, Robert,Frauchiger, Sandra,La Fargue, Joann,Ghate, Manjiri,Graves, Bradford,Hill, Ronald J.,Li, Fujun,Litman, Renee,Loe, Brad,McIntosh, Joel,McWeeney, Daniel,Papp, Eva,Park, Jaehyeon,Reese, Harlan F.,Roberts, Richard T.,Rotstein, David,San Pablo, Bong,Sarma, Keshab,Stahl, Martin,Sung, Man-Ling,Suttman, Rebecca T.,Sjogren, Eric B.,Tan, Yunchou,Trejo, Alejandra,Welch, Mary,Weller, Paul,Wong, Brian R.,Zecic, Hasim

, p. 2255 - 2265 (2011/06/21)

The development of a new series of p38α inhibitors resulted in the identification of two clinical candidates, one of which was advanced into a phase 2 clinical study for rheumatoid arthritis. The original lead, an lck inhibitor that also potently inhibited p38α, was a screening hit from our kinase inhibitor library. This manuscript describes the optimization of the lead to p38-selective examples with good pharmacokinetic properties.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 449808-50-8